Stoneridge Investment Partners LLC cut its position in shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 58.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,166 shares of the company’s stock after selling 30,132 shares during the period. Stoneridge Investment Partners LLC’s holdings in Zimmer Biomet Holdings were worth $2,548,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ZBH. Park Avenue Institutional Advisers LLC raised its position in Zimmer Biomet Holdings by 1.2% in the first quarter. Park Avenue Institutional Advisers LLC now owns 1,128 shares of the company’s stock worth $120,000 after buying an additional 13 shares during the last quarter. IFP Advisors Inc raised its position in Zimmer Biomet Holdings by 27.9% in the first quarter. IFP Advisors Inc now owns 1,499 shares of the company’s stock worth $160,000 after buying an additional 327 shares during the last quarter. Regent Investment Management LLC purchased a new position in Zimmer Biomet Holdings during the second quarter worth about $217,000. Checchi Capital Advisers LLC raised its position in Zimmer Biomet Holdings by 3.7% in the second quarter. Checchi Capital Advisers LLC now owns 1,832 shares of the company’s stock worth $221,000 after buying an additional 66 shares during the last quarter. Finally, Atria Investments LLC purchased a new position in Zimmer Biomet Holdings during the second quarter worth about $238,000. Institutional investors and hedge funds own 88.30% of the company’s stock.

Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded up 2.12% during midday trading on Wednesday, hitting $127.19. 896,658 shares of the company were exchanged. The stock has a market capitalization of $25.44 billion, a PE ratio of 116.16 and a beta of 0.95. The firm’s 50-day moving average price is $128.38 and its 200-day moving average price is $119.25. Zimmer Biomet Holdings Inc. has a one year low of $88.27 and a one year high of $133.19.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Thursday, July 28th. The company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.97 by $0.05. The business earned $1.93 billion during the quarter, compared to analyst estimates of $1.90 billion. Zimmer Biomet Holdings had a net margin of 1.68% and a return on equity of 16.12%. The firm’s quarterly revenue was up 65.6% on a year-over-year basis. During the same quarter last year, the business earned $1.58 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings Inc. will post $7.97 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 23rd will be issued a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, September 21st. This represents a $0.96 dividend on an annualized basis and a yield of 0.75%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 157.38%.

Several analysts have issued reports on the stock. Barclays PLC raised their price target on shares of Zimmer Biomet Holdings from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Friday, July 29th. Morgan Stanley restated a “buy” rating on shares of Zimmer Biomet Holdings in a research report on Wednesday, June 8th. Needham & Company LLC raised their price target on shares of Zimmer Biomet Holdings from $143.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, July 29th. JMP Securities raised their price target on shares of Zimmer Biomet Holdings from $131.00 to $145.00 and gave the stock a “market outperform” rating in a research report on Friday, July 29th. Finally, BMO Capital Markets restated a “buy” rating and issued a $146.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, July 29th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-two have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $132.36.

In other Zimmer Biomet Holdings news, insider Daniel E. Williamson sold 2,716 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $129.96, for a total transaction of $352,971.36. Following the completion of the transaction, the insider now owns 2,000 shares in the company, valued at approximately $259,920. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Daniel P. Florin sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $124.98, for a total transaction of $1,874,700.00. Following the transaction, the chief financial officer now owns 16,983 shares of the company’s stock, valued at approximately $2,122,535.34. The disclosure for this sale can be found here. 1.22% of the stock is currently owned by corporate insiders.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc. (NYSE:ZBH).

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.